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usage data. By potentially avoiding a diagnosis of HIT/HITT in
these patients, the hospital would realize an annualized savings
of over $86,000.
Conclusion: Normal saline has demonstrated historical
noninferiority to heparin for maintaining PICC patency when
used as the capping solution with positive pressurized caps.
Similar results were found during our pilot.
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Background: With over 40 years of demonstrated clinical
efficacy, warfarin remains the world’s most used pharmaceutical
to prevent ischemic stroke in patients with atrial fibrillation
(AF). However, warfarin has many challenges. Thus, despite
known effectiveness, warfarin is a leading cause to druginduced morbidity and mortality. Over 50 different warfarin
therapy protocols, including a number of pharmacogenomicbased (PG) protocols, with as many as 14 independent variables,
have been developed to improve safety and efficacy, thereby
reducing ischemic strokes and intracranial hemorrhages (ICH).
Purpose: To conduct a preliminary cost-effectiveness study to
determine the price point at which using warfarin PG dosing to
prevent ischemic stroke and ICH would provide a neutral cost
difference for the AF patient population at Aurora Health Care.
Methods: Using a 15-year retrospective electronic medical
record, we generated a large enough simulated AF population
using Bayesian Network modeling to conduct a series of
simulated warfarin therapies. We used five different PG and
non-PG warfarin therapy protocols. The protocols with various
levels of personalization used different PG and non-PG dosing
algorithms for initial, adjustment and maintenance warfarin
dosing. The simulation platform was able to predict daily
international normalized ratio values and the rate of ischemic
stroke and ICH in each simulated patient over 90 days for
each of the five warfarin therapy protocols. Using nationwide
estimates derived through literature review, we estimated the
total cost of administering warfarin using the five different
protocols and subsequent acute and 5-year care costs (adjusted
according to annual Medical Care Component of the Consumer
Price Index).
Results: In 2000–2015, a total of 48,006 patients, or ~3,000
patients annually, initiated warfarin therapy with a primary
diagnosis of AF at Aurora. We found that Aurora’s current best
practice warfarin therapy protocol had the highest predicted
costs for ICH, resulting in $163,462.55 for acute care costs
(averaged over 1,000 patients) and $171,279.60 for 5-year
ongoing care related to ICH. The current Aurora protocol
also had the highest associated costs for ischemic stroke at
$51,333.45 for acute care and $58,507.21 for 5-year ongoing
care. In contrast, PG-protocol 3, which incorporated patient’s
genotype into the warfarin dosing protocol, had the lowest
predicted acute care and ongoing costs associated with ICH at
$119,823.78 for acute care and $125,462.75 for ongoing care.
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For 1,000 AF patients initiating warfarin therapy in Aurora,
switching to a PG protocol would save $55,299.94 in acute care
costs and $59,198.50 in 5-year ongoing care.
Conclusion: At a cost of $59.20 per patient, warfarin PG
dosing is cost neutral. With substantial decreases in genotyping
cost in recent years, it is likely this price is currently achievable.
Therefore, although there is only incremental clinical benefit
from warfarin PG dosing, it is likely cost-effective.
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Background: The Institute for Healthcare Improvement’s Triple
Aim focuses on improving the patient’s experience of care,
improving population health and reducing the per capita cost
of health care. Health care systems and providers continuously
seek to improve quality of care through understanding what
percentage of their patients are achieving quality-of-care
standards for various indicators, including immunizations,
tobacco cessation, asthma and cancer screening. As health care
moves toward reimbursing for value-based care, deepening our
understanding of patient population characteristics within each
of these conditions is vital to continuous quality improvement.
Purpose: To determine if there are race/ethnicity/age/preferred
language (REAL) disparities in care to patients 50 years old or
older who are eligible for colorectal cancer (CRC) screening in
family medicine residency clinics.
Methods: A retrospective analysis of all patients eligible for
CRC screening at two Milwaukee-based family medicine
residency teaching clinics (referred to as FM1 and FM2) and
nonacademic clinics in greater Milwaukee (NAC-MKE) during
a 12-month period (December 2014 – November 2015) was
undertaken in collaboration with health care system quality
improvement specialists. Percentage of patients achieving
CRC screening metric was reported by REAL and gender.
As the ultimate goal was to identify subpopulations to target
for improvement, categories with N < 25 were omitted and
criterion for disparity within a category was defined as > 10%.
Results: The largest CRC screening disparity was associated
with age, with gaps ranging from 13% to 15% between
populations > 65 years old versus 50–54 years old: NAC-MKE
(79% vs 66%), FM1 (81% vs 68%), and FM2 (80% vs 65%).
CRC screening disparities varied by black/African-American
race per location, 54% at NAC-MKE and 67% at FM2 (N ≤ 25
at FM1). Other race, ethnicity and gender were < 10%.
Conclusion: Per the Centers for Disease Control and
Prevention, the African-American/black race has the highest
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